BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lim J, Song YJ, Park WS, Sohn H, Lee MS, Shin DH, Kim CB, Kim H, Oh GJ, Ki M. The immunogenicity of a single dose of hepatitis A virus vaccines (Havrix® and Epaxal®) in Korean young adults. Yonsei Med J 2014;55:126-31. [PMID: 24339297 DOI: 10.3349/ymj.2014.55.1.126] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Singh SK, Kumar U, Guleria A, Kumar D. A brief overview about the use of different bioactive liposome-based drug delivery systems in Peritoneal Dialysis and some other diseases. Nano Ex 2021;2:022006. [DOI: 10.1088/2632-959x/abfdd1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Van Herck K, Hens A, De Coster I, Vertruyen A, Tolboom J, Sarnecki M, Van Damme P. Long-term antibody persistence in children after vaccination with the pediatric formulation of an aluminum-free virosomal hepatitis A vaccine. Pediatr Infect Dis J 2015;34:e85-91. [PMID: 25389920 DOI: 10.1097/INF.0000000000000616] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
3 Beltrán-gracia E, López-camacho A, Higuera-ciapara I, Velázquez-fernández JB, Vallejo-cardona AA. Nanomedicine review: clinical developments in liposomal applications. Cancer Nano 2019;10. [DOI: 10.1186/s12645-019-0055-y] [Cited by in Crossref: 77] [Cited by in F6Publishing: 23] [Article Influence: 25.7] [Reference Citation Analysis]
4 Tagliabue C, Principi N, Giavoli C, Esposito S. Obesity: impact of infections and response to vaccines. Eur J Clin Microbiol Infect Dis 2016;35:325-31. [PMID: 26718941 DOI: 10.1007/s10096-015-2558-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
5 Guiren Fritah H, Rovelli R, Lai-lai Chiang C, Kandalaft LE. The current clinical landscape of personalized cancer vaccines. Cancer Treatment Reviews 2022. [DOI: 10.1016/j.ctrv.2022.102383] [Reference Citation Analysis]
6 Dhurandhar NV, Bailey D, Thomas D. Interaction of obesity and infections. Obes Rev. 2015;16:1017-1029. [PMID: 26354800 DOI: 10.1111/obr.12320] [Cited by in Crossref: 71] [Cited by in F6Publishing: 56] [Article Influence: 10.1] [Reference Citation Analysis]
7 Zimmermann P, Curtis N. Factors That Influence the Immune Response to Vaccination. Clin Microbiol Rev. 2019;32. [PMID: 30867162 DOI: 10.1128/cmr.00084-18] [Cited by in Crossref: 132] [Cited by in F6Publishing: 74] [Article Influence: 44.0] [Reference Citation Analysis]
8 Painter SD, Ovsyannikova IG, Poland GA. The weight of obesity on the human immune response to vaccination. Vaccine 2015;33:4422-9. [PMID: 26163925 DOI: 10.1016/j.vaccine.2015.06.101] [Cited by in Crossref: 82] [Cited by in F6Publishing: 70] [Article Influence: 11.7] [Reference Citation Analysis]
9 Song YJ, Lim J, Park WS, Sohn H, Lee MS, Shin DH, Kim CB, Kim H, Oh GJ, Ki M. Seropositivity among Korean Young Adults Approximately 2 Years after a Single-Dose Vaccination against Hepatitis A Virus. PLoS One 2015;10:e0142297. [PMID: 26540392 DOI: 10.1371/journal.pone.0142297] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
10 Kabir A, Lotfi S, Farsi F, Pazouki A. Impact of body mass index on immunogenicity of hepatitis B vaccine in bariatric surgery candidates: A retrospective study. Diabetes Metab Syndr 2021;15:102254. [PMID: 34450550 DOI: 10.1016/j.dsx.2021.102254] [Reference Citation Analysis]
11 Nardo D, Henson D, Springer JE, Venditto VJ. Modulating the immune response with liposomal delivery. Nanomaterials for Clinical Applications. Elsevier; 2020. pp. 159-211. [DOI: 10.1016/b978-0-12-816705-2.00006-0] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Liu J, Miao L, Sui J, Hao Y, Huang G. Nanoparticle cancer vaccines: Design considerations and recent advances. Asian J Pharm Sci 2020;15:576-90. [PMID: 33193861 DOI: 10.1016/j.ajps.2019.10.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
13 Dumrisilp T, Wongpiyabovorn J, Buranapraditkun S, Tubjaroen C, Chaijitraruch N, Prachuapthunyachart S, Sintusek P, Chongsrisawat V. Impact of Obesity and Being Overweight on the Immunogenicity to Live Attenuated Hepatitis A Vaccine in Children and Young Adults. Vaccines (Basel) 2021;9:130. [PMID: 33562009 DOI: 10.3390/vaccines9020130] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Juliao P, Abadia I, Welby S, Wéry S, Wong D, De Léon T, DeAntonio R, Naranjo L, Guignard A, Marano C. Hepatitis A antibody persistence 8 and 10 years after 1-dose and 2-dose vaccination in children from Panama. Vaccine 2021;39:26-34. [PMID: 33239226 DOI: 10.1016/j.vaccine.2020.11.030] [Reference Citation Analysis]
15 Yoon SH, Kim HW, Ahn JG, Kim IT, Kim JH, Kong KA, Kim KH. Reappraisal of the Immunogenicity and Safety of Three Hepatitis A Vaccines in Adolescents. J Korean Med Sci 2016;31:73-9. [PMID: 26770041 DOI: 10.3346/jkms.2016.31.1.73] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
16 Chappuis F, Farinelli T, Deckx H, Sarnecki M, Go O, Salzgeber Y, Stals C. Immunogenicity and estimation of antibody persistence following vaccination with an inactivated virosomal hepatitis A vaccine in adults: A 20-year follow-up study. Vaccine 2017;35:1448-54. [PMID: 28190741 DOI: 10.1016/j.vaccine.2017.01.031] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
17 Petráš M, Oleár V. Predictors of the immune response to booster immunisation against tetanus in Czech healthy adults. Epidemiol Infect 2018;146:2079-85. [PMID: 30136643 DOI: 10.1017/S095026881800242X] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]